Abacus Planning Group Inc. Acquires 452 Shares of Johnson & Johnson $JNJ

Abacus Planning Group Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the second quarter, Holdings Channel.com reports. The fund owned 10,482 shares of the company’s stock after buying an additional 452 shares during the period. Abacus Planning Group Inc.’s holdings in Johnson & Johnson were worth $1,601,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.4%

JNJ opened at $188.51 on Friday. The firm has a market cap of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average of $176.18 and a 200 day moving average of $162.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on JNJ shares. Weiss Ratings restated a “hold (c+)” rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Citigroup raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Royal Bank Of Canada raised their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Finally, HSBC raised their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $188.88.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.